Our Past Achievements and Future Outlook
Our vaccine research and development journey started with a strategic partnership with UMN Pharma in 2017. This collaboration escalated when UMN Pharma became a subsidiary of SHIONOGI in March 2020, thereby fast-tracking our work on vaccines against infectious diseases.
As a leading company in the infectious diseases field, we are concentrating resources on the development of vaccines and treatments for COVID-19, which caused the pandemic, leveraging external partnerships. Simultaneously, we have been advancing our research and development of proprietary adjuvants. In June 2024, SHIONOGI obtained domestic manufacturing and marketing approval for our first recombinant protein vaccine, "COVGOZE," along with the use of our in-house adjuvants.
Beyond this, we are involved in various other vaccine-related initiatives. In the infectious diseases domain, we are actively researching universal vaccines capable of dealing with viral mutations and next-generation intranasal vaccines. Additionally, in collaboration with external partners, we are advancing research on therapeutic vaccines for conditions like Hepatitis B.
Please check the details from the link below.